Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders: Preclinical studies and pharmaceutical design

János Tajti, Zsófia Majláth, Délia Szok, Anett Csáti, József Toldi, Ferenc Fülöp, László Vécsei

Research output: Contribution to journalArticle

6 Citations (Scopus)


Though migraine and neurodegenerative disorders have a high socioeconomic impact, their therapeutic management has not been fully addressed. Their pathomechanisms are not completely understood, but glutamateinduced excitotoxicity, mitochondrial disturbances and oxidative stress all seem to play crucial roles. The overactivation of glutamate receptors contributes to the hyperexcitability observed in migraine and also to the neurodegenerative process. The kynurenine pathway of the tryptophan metabolism produces the only known endogenous Nmethyl-D-aspartate receptor antagonist, kynurenic acid, which has been proven in different preclinical studies toexert a neuroprotective effect. Influencing the kynurenine pathway might be beneficial in migraine and neurodegenerative diseases, and in the normalization of glutamatergic neurotransmission and the prevention of excitotoxic neuronal damage. Thesynthesis of kynurenic acid analogues may offer a valuable tool for drug development.

Original languageEnglish
Pages (from-to)2250-2258
Number of pages9
JournalCurrent pharmaceutical design
Issue number17
Publication statusPublished - May 1 2015



  • Hyperexcitability
  • Kynurenic acid
  • Kynurenic acid analogues
  • Migraine
  • Neurodegeneration
  • Neuroprotection

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this